Research analysts at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a research note issued on Friday. The firm set a “sell” rating on the medical technology company’s stock.
Other equities analysts have also issued reports about the stock. Benchmark reiterated a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets lowered their target price on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.
Check Out Our Latest Stock Analysis on BIOLASE
BIOLASE Stock Performance
Hedge Funds Weigh In On BIOLASE
An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC increased its position in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the period. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is owned by institutional investors and hedge funds.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Articles
- Five stocks we like better than BIOLASE
- Stock Splits, Do They Really Impact Investors?
- Fast-Growing Companies That Are Still Undervalued
- Consumer Staples Stocks, Explained
- Top Cybersecurity Stock Picks for 2025
- How to trade using analyst ratings
- Archer or Joby: Which Aviation Company Might Rise Fastest?
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.
